Aldeyra Therapeutics, Inc.
ALDX
$1.86
$0.031.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -8.02% | 54.52% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.66% | -21.32% | |||
| Operating Income | 16.66% | 21.32% | |||
| Income Before Tax | 15.96% | 21.29% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 15.96% | 21.29% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 15.96% | 21.29% | |||
| EBIT | 16.66% | 21.32% | |||
| EBITDA | 16.81% | 21.46% | |||
| EPS Basic | 16.03% | 21.39% | |||
| Normalized Basic EPS | 16.02% | 21.44% | |||
| EPS Diluted | 16.03% | 21.39% | |||
| Normalized Diluted EPS | 16.02% | 21.44% | |||
| Average Basic Shares Outstanding | 0.06% | 0.14% | |||
| Average Diluted Shares Outstanding | 0.06% | 0.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||